Quick Takeaways
- Merck Animal Health has secured US FDA approval for Numelvi (atinvicitinib tablets), the first and only second-generation JAK inhibitor for controlling pruritus linked to allergic dermatitis in dogs aged 6 months and older.
- Numelvi is a once-daily, first-line therapy that delivers rapid itch relief from the first dose, with high JAK1 selectivity, helping reduce inflammation while maintaining a strong safety profile. It also offers convenient dosing, no vaccine schedule adjustments, and long shelf life.
- Expected to launch in spring 2026 across US veterinary clinics, the therapy addresses a major unmet need, as skin conditions account for up to 20% of vet visits, significantly impacting dogs’ quality of life and pet-owner well-being.
Why It Matters?
Merck Animal Health strengthens its dermatology franchise with a differentiated, second-generation JAK inhibitor positioned as a convenient, first-line option for allergic pruritus.
Once-daily dosing and rapid onset are likely to shift prescribing from older therapies (including steroids and first-generation JAK inhibitors), increasing brand loyalty among dermatology-focused veterinarians.
Given the high share of skin cases in small-animal practice, Numelvi can become a key driver of clinic revenue and deepen Merck’s integration into chronic care protocols for companion animals.
Source: Businesswire
